A Fas promoter polymorphism at position -670 in the enhancer region does not confer susceptibility to Felty's and large granular lymphocyte syndromes

Rheumatology

Volumn 38, Issue 9, 1999, Pages 883-886

  Coakley, G ^a   Manolios, N ^b   Loughran Jr , T P ^c   Panayi, G S ^a   Lanchbury, J S ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Fas; Fas ligand; Felty's syndrome; Large granular lymphocyte; Polymorphism; Rheumatoid arthritis

Indexed keywords

FAS LIGAND; RESTRICTION ENDONUCLEASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENHANCER REGION; FELTY SYNDROME; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LARGE GRANULAR LYMPHOCYTE; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RHEUMATOID ARTHRITIS; RISK FACTOR;

AGED; AGED, 80 AND OVER; ALLELES; ANTIGENS, CD95; ARTHRITIS, RHEUMATOID; ENHANCER ELEMENTS (GENETICS); FELTY'S SYNDROME; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LEUKEMIA, LYMPHOCYTIC; LYMPHOCYTES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS);

EID: 0032704386     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.9.883     Document Type: Article

References (23)

1. Bowman SJ, Bhavnani M, Geddes GC et al. Large granular lymphocyte expansions in patients with Felty's syndrome: analysis using anti-T cell receptor V beta-specific monoclonal antibodies. Clin Exp Immunol 1995;101: 18-24.
2. Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood 1993;82:1-14.
3. Bowman SJ, Sivakumaran M, Snowden N et al. The large granular lymphocyte syndrome with rheumatoid arthritis. Immunogenetic evidence for a broader definition of Felty's syndrome. Arthritis Rheum 1994;37:1326-30.
4. Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995;16:569-74.
5. Behrmann I, Walczak H, Krammer PH. Structure of the human APO-1 gene. Eur J Immunol 1994;24:3057-62.
6. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356:314-7.
7. Wu J, Zhou T, He J, Mountz JD. Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. J Exp Med 1993;178:461-8.
8. Rieux-Laucat F, Le Deist F, Hivroz C et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268:1347-9.
9. Fisher GH, Rosenberg FJ, Straus SE et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-46.
10. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997;34:577-82.
11. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
12. Bowman SJ, Corrigall V, Panayi GS, Lanchbury JS. Hematologic and cytofluorographic analysis of patients with Felty's syndrome. A hypothesis that a discrete event leads to large granular lymphocyte expansions in this condition. Arthritis Rheum 1995;38:1252-9.
13. Starkebaum G, Loughran TP Jr, Gaur LK, Davis P, Nepom BS. Immunogenetic similarities between patients with Felty's syndrome and those with clonal expansions of large granular lymphocytes in rheumatoid arthritis. Arthritis Rheum 1997;40:624-6.
14. Coakley G, Mok CC, Hajeer AH et al. Interleukin-10 promoter polymorphisms in rheumatoid arthritis and Felty's syndrome. Br J Rheumatol 1998;37:988-91.
15. Miyawaki T, Uehara T, Nibu R et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol 1992;149:3753-8.
16. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997;186:2045-50.
17. Lamy T, Liu JH, Landowski TH, Dalton WS, Loughran TP. Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia. Blood 1998;92:4771-7.
18. Tanaka M, Suda T, Haze K et al. Fas ligand in human serum. Nature Med 1996;2:317-22.
19. Perzova R, Loughran TP Jr. Constitutive expression of Fas ligand in large granular lymphocyte leukaemia. Br J Haematol 1997;97:123-6.
20. Hahne M, Rimoldi D, Schroter M et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-6.
21. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995;377:630-2.
22. Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997;94:3943-7.
23. Nagata S. Apoptosis by death factor. Cell 1997;88:355-65.